Companies Spyre Therapeutics, Inc.
Spyre Therapeutics (SYRE): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Spyre Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers61st pct.Of 18 peer CEOs
CEO pay, last three years
- $15,919,545FY2023
- $6,960,186FY2024
- $6,707,361FY2025
CEO total pay was $6,707,361 in fiscal 2025, down from $6,960,186 in fiscal 2024.
FY2025: salary $665,000 · bonus $0 · stock awards $0 · option awards $5,552,886
Executives and directors
Cameron Turtle · CEOHeidy King-Jones · General CounselScott Burrows · CFOSheldon Sloan · Chief Medical OfficerJeffrey Albers · Chair of the BoardLaurie Stelzer · Independent DirectorMark McKenna · DirectorMichael Henderson · Independent DirectorPeter Harwin · Independent DirectorSandra Milligan · Independent DirectorTomas Kiselak · Independent Director
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Cameron Turtle | $665,000 | $0 | $0 | $5,552,886 | $475,475 | $0 | $14,000 | $6,707,361 |
| Chief Executive Officer | ||||||||
| Sheldon Sloan | 503,000 | 0 | 0 | 1,433,245 | 261,560 | 0 | 14,000 | 2,211,805 |
| Chief Medical Officer | ||||||||
| Heidy King-Jones | 490,000 | 0 | 0 | 1,433,245 | 254,800 | 0 | 14,000 | 2,192,045 |
| Chief Legal Officer and Corporate Secretary | ||||||||
| Scott Burrows | 490,000 | 0 | 0 | 1,433,245 | 254,800 | 0 | 14,000 | 2,192,045 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Cameron Turtle | $6,707,361 | $6,960,186 | $15,919,545 | ↓ −252,825 |
| Sheldon Sloan | 2,211,805 | 9,388,740 | — | ↓ −7,176,935 |
| Heidy King-Jones | 2,192,045 | 2,051,909 | 6,588,281 | ↑ +140,136 |
| Scott Burrows | 2,192,045 | 2,207,366 | 7,551,539 | ↓ −15,321 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is to provide market-competitive compensation that emphasizes at-risk cash bonus opportunities and equity compensation reflecting performance goals and scope of responsibility. The program aims to align executive pay with Company performance and stockholder interests, attract and retain talent, and maintain a significant portion of compensation at risk to promote a 'pay for performance' culture.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Cameron Turtle | OPTION | 2025-01-15 | — | — | 370,000 | — | $5,552,886 |
| Heidy King-Jones | OPTION | 2025-01-15 | — | — | 95,500 | — | 1,433,245 |
| Scott Burrows | OPTION | 2025-01-15 | — | — | 95,500 | — | 1,433,245 |
| Sheldon Sloan | OPTION | 2025-01-15 | — | — | 95,500 | — | 1,433,245 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Cameron Turtle | $0 | $0 | $5,552,886 | 0.0% |
| Heidy King-Jones | 0 | 0 | 1,433,245 | 0.0% |
| Scott Burrows | 0 | 0 | 1,433,245 | 0.0% |
| Sheldon Sloan | 0 | 0 | 1,433,245 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Heidy King-Jones | Option | 34,125 | 25.86 | — |
| Scott Burrows | Option | 37,917 | 25.86 | — |
| Scott Burrows | RSU | 67,476 | — | 2,210,514 |
| Scott Burrows | Option | 73,615 | 21.66 | — |
| Sheldon Sloan | Option | 73,615 | 21.66 | — |
| Heidy King-Jones | Option | 73,615 | 21.66 | — |
| Cameron Turtle | Option | 150,448 | 25.86 | — |
| Cameron Turtle | RSU | 159,713 | — | 5,232,198 |
| Scott Burrows | Option | 177,126 | 14.5 | — |
| Cameron Turtle | Option | 179,209 | 10.39 | — |
| Heidy King-Jones | Option | 236,168 | 14.5 | — |
| Sheldon Sloan | Option | 283,334 | 27.46 | — |
| Cameron Turtle | Option | 285,209 | 21.66 | — |
| Cameron Turtle | Option | 709,458 | 7.5 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey AlbersIndependent · Audit Committee · Compensation Committee (Chair) | $100,000 | $0 | $248,675 | — | $0 | $348,675 |
| Laurie StelzerIndependent · Audit Committee (Chair) · Nominating Committee | 65,000 | 0 | 248,675 | — | 0 | 313,675 |
| Sandra MilliganIndependent · Compensation Committee · Nominating Committee (Chair) | 57,500 | 0 | 248,675 | — | 0 | 306,175 |
| Michael HendersonIndependent · Audit Committee | 50,000 | 0 | 248,675 | — | 0 | 298,675 |
| Tomas KiselakIndependent · Compensation Committee | 47,500 | 0 | 248,675 | — | 0 | 296,175 |
| Peter HarwinIndependent · Nominating Committee | 45,000 | 0 | 248,675 | — | 0 | 293,675 |
| Mark McKennaNot independent | 40,000 | 0 | 248,675 | — | 0 | 288,675 |
| Cameron TurtleEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $405,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $405,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Spyre Therapeutics as a peer
Companies that benchmark against SYRE
6 companies name SYRE as a compensation peer
- AbCellera Biologics Inc.ABCLFY2025
- Apogee Therapeutics, Inc.APGEFY2025
- Dianthus Therapeutics, Inc. /DE/DNTHFY2025
- Jade Biosciences, Inc.JBIOFY2025
- Trevi Therapeutics, Inc.TRVIFY2025
- Vera Therapeutics, Inc.VERAFY2025
Each company listed discloses SYRE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SYRE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
APGE Apogee Therapeutics, Inc.VERA Vera Therapeutics, Inc.PLRX Pliant Therapeutics, Inc.ACLX Arcellx, Inc.ATXS Astria Therapeutics, Inc.IGMS IGM Biosciences, Inc.STOK Stoke Therapeutics, Inc.ANAB AnaptysBio, Inc.CLDX Celldex Therapeutics, Inc.KROS Keros Therapeutics, Inc.XNCR Xencor Inc.JANX Janux Therapeutics, Inc.NRIX Nurix Therapeutics, Inc.CTNM Contineum Therapeutics, Inc.IRON Disc Medicine, Inc.KYMR Kymera Therapeutics, Inc.DYN Dyne Therapeutics, Inc.GPCR Structure Therapeutics Inc.
Peer reciprocity
Of the companies Spyre Therapeutics, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
✓ Apogee Therapeutics, Inc. (APGE)156✓ Vera Therapeutics, Inc. (VERA)157— Pliant Therapeutics, Inc. (PLRX)158— Arcellx, Inc. (ACLX)159— Astria Therapeutics, Inc. (ATXS)160— IGM Biosciences, Inc. (IGMS)161— Stoke Therapeutics, Inc. (STOK)162— AnaptysBio, Inc. (ANAB)163— Celldex Therapeutics, Inc. (CLDX)164— Keros Therapeutics, Inc. (KROS)165— Xencor Inc. (XNCR)166— Janux Therapeutics, Inc. (JANX)167— Nurix Therapeutics, Inc. (NRIX)168— Contineum Therapeutics, Inc. (CTNM)169— Disc Medicine, Inc. (IRON)170— Kymera Therapeutics, Inc. (KYMR)171— Dyne Therapeutics, Inc. (DYN)172— Structure Therapeutics Inc. (GPCR)173
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Spyre Therapeutics, Inc..
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Arcellx, Inc. | 2024 | Rami Elghandour | 653,288 | 9,342,069 | 10,850,151 | 0 | 21,402,668 |
| 3 | Janux Therapeutics, Inc. | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 4 | Disc Medicine, Inc. | 2025 | John Quisel | 695,000 | 4,285,817 | 4,441,046 | 554,263 | 9,986,626 |
| 5 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 6 | Structure Therapeutics Inc. | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 7 | Vera Therapeutics, Inc. | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 8 | Spyre Therapeutics, Inc. | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 9 | Astria Therapeutics, Inc. | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 10 | Nurix Therapeutics, Inc. | 2025 | Arthur Sands | 674,584 | 0 | 5,166,196 | 510,000 | 6,374,138 |
| 11 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 12 | Xencor Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 13 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 14 | Celldex Therapeutics, Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 15 | Contineum Therapeutics, Inc. | 2025 | Carmine Stengone | 655,620 | 0 | 2,291,640 | 450,739 | 3,409,448 |
| 16 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 17 | Keros Therapeutics, Inc. | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 18 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 19 | Apogee Therapeutics, Inc. | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Spyre Therapeutics, Inc. | 130% | Option 100 | not disclosed | Alpine Rewards |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Apogee Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Arcellx, Inc. | 140% | not disclosed | No | Meridian Compensation Partners |
| Astria Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Celldex Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Contineum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine |
| Disc Medicine, Inc. | 145% | RSU 50 · Options 50 | not disclosed | Pearl Meyer |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Janux Therapeutics, Inc. | 90% | not disclosed | not disclosed | FW Cook |
| Keros Therapeutics, Inc. | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Nurix Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Pliant Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Structure Therapeutics Inc. | 125% | Options 67 · RSU 33 | No | Aon |
| Vera Therapeutics, Inc. | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
| Xencor Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 15 : 1 |
|---|---|
| CEO total compensation | $6,707,361 |
| Median employee compensation | $437,242 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Cameron Turtle | Director | 2026-05-01 | D | 300 | $75 | $22,488 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 3,100 | 73 | 226,734 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 1,000 | 72 | 71,760 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 3,600 | 71 | 254,772 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 78,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 400 | 75 | 30,148 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 5,059 | 75 | 377,401 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 10,358 | 74 | 763,799 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 8,777 | 72 | 628,082 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 19,656 | 71 | 1,387,910 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 21,306 | 70 | 1,481,406 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-05-01 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-05-01 | A | 12,500 | 15 | 181,250 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 12,777 | 73 | 931,954 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | A | 78,333 | 27 | 2,151,024 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-05-01 | D | 12,500 | 71 | 892,125 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 5,300 | 70 | 368,562 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 1,700 | 74 | 126,191 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 19,269 | 75 | 1,451,919 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 24,814 | 75 | 1,855,095 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 33,513 | 74 | 2,470,578 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 2,404 | 73 | 174,458 | Common | Form 4 ↗ |
| Sandra Milligan | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Stelzer | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark McKenna | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 3,100 | 72 | 223,386 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 2,599 | 71 | 183,931 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-06-01 | D | 3,557 | 69 | 246,856 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 1,801 | 70 | 125,620 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-06-01 | D | 8,149 | 71 | 574,505 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-06-01 | D | 3,294 | 71 | 235,126 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-06-03 | D | 8,333 | 75 | 624,975 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-06-03 | A | 8,333 | 27 | 228,824 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-06-03 | D | 8,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-06-22 | D | 20,000 | 100 | 2,000,000 | Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-06-23 | D | 16,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-06-23 | D | 4,684,781 | 85 | 399,658,667 | Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-06-23 | A | 666,680 | — | — | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | A | 15,000 | 15 | 217,500 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | D | 5,000 | 87 | 435,600 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | D | 10,000 | 87 | 871,400 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | D | 1,725 | 88 | 152,438 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-07-01 | D | 4,234 | 88 | 373,100 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | D | 6,500 | 88 | 568,880 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | A | 8,334 | 27 | 228,852 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-07-01 | D | 10,176 | 87 | 889,789 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | D | 8,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | D | 1,834 | 88 | 162,016 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | D | 5,775 | 88 | 505,601 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-07-01 | D | 590 | 89 | 52,457 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 16 | 97 | 1,559 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 800 | 94 | 75,176 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 100 | 97 | 9,710 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 2,300 | 96 | 221,490 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 5,100 | 95 | 485,571 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 5,635 | 96 | 540,566 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 7,157 | 95 | 680,631 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 1,392 | 97 | 134,773 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 5,000 | 104 | 522,350 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | A | 5,000 | 10 | 51,950 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 8,000 | 104 | 835,040 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 10,000 | 105 | 1,046,800 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 400 | 89 | 35,628 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 8,400 | 87 | 732,060 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 2,500 | 86 | 215,900 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 200 | 89 | 17,808 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 27,999 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 400 | 89 | 35,752 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 6,206 | 88 | 547,183 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 16,548 | 87 | 1,442,986 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | A | 27,999 | 15 | 405,986 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 4,845 | 86 | 418,608 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 2,016 | 88 | 177,468 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 4,384 | 87 | 381,890 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 900 | 86 | 77,625 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 3,700 | 88 | 325,822 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-02 | D | 18,232 | 89 | 1,629,029 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-02 | D | 400 | 90 | 36,000 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-02 | A | 400 | 15 | 5,800 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-02 | — | 400 | — | — | 1 insider, 1 accrual row | ||
| Scott Burrows | Chief Financial Officer | 2026-09-30 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-30 | D | 17,500 | 90 | 1,573,075 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-30 | A | 17,500 | 15 | 253,750 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 2,600 | 93 | 242,996 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 2,100 | 93 | 194,670 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 7,228 | 91 | 660,278 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 16,605 | 90 | 1,500,262 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 400 | 89 | 35,696 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | A | 28,933 | 15 | 419,529 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 229 | 94 | 21,428 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 3,071 | 93 | 285,449 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 2,100 | 92 | 193,032 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 600 | 89 | 53,442 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 100 | 94 | 9,391 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 4,990 | 93 | 465,916 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 3,989 | 92 | 368,225 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 2,638 | 91 | 241,351 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 2,683 | 90 | 241,738 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 600 | 89 | 53,484 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 28,933 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 1,500 | 90 | 135,405 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 116 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Cameron Turtle | Director | 2026-05-01 | D | 300 | $75 | $22,488 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 3,100 | 73 | 226,734 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 1,000 | 72 | 71,760 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 3,600 | 71 | 254,772 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 78,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 400 | 75 | 30,148 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 5,059 | 75 | 377,401 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 10,358 | 74 | 763,799 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 8,777 | 72 | 628,082 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 19,656 | 71 | 1,387,910 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 21,306 | 70 | 1,481,406 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-05-01 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-05-01 | A | 12,500 | 15 | 181,250 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | D | 12,777 | 73 | 931,954 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-05-01 | A | 78,333 | 27 | 2,151,024 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-05-01 | D | 12,500 | 71 | 892,125 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 5,300 | 70 | 368,562 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-05-01 | D | 1,700 | 74 | 126,191 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 19,269 | 75 | 1,451,919 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 24,814 | 75 | 1,855,095 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 33,513 | 74 | 2,470,578 | Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-08 | D | 2,404 | 73 | 174,458 | Common | Form 4 ↗ |
| Sandra Milligan | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Stelzer | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark McKenna | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-05-27 | A | 8,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 3,100 | 72 | 223,386 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 2,599 | 71 | 183,931 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-06-01 | D | 3,557 | 69 | 246,856 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-01 | D | 1,801 | 70 | 125,620 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-06-01 | D | 8,149 | 71 | 574,505 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-06-01 | D | 3,294 | 71 | 235,126 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-06-03 | D | 8,333 | 75 | 624,975 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-06-03 | A | 8,333 | 27 | 228,824 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-06-03 | D | 8,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Henderson | Director | 2026-06-22 | D | 20,000 | 100 | 2,000,000 | Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-06-23 | D | 16,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-06-23 | D | 4,684,781 | 85 | 399,658,667 | Common | Form 4 ↗ |
| Fairmount Funds Management LLC | Director | 2026-06-23 | A | 666,680 | — | — | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | A | 15,000 | 15 | 217,500 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | D | 5,000 | 87 | 435,600 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-06-25 | D | 10,000 | 87 | 871,400 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | D | 1,725 | 88 | 152,438 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-07-01 | D | 4,234 | 88 | 373,100 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | D | 6,500 | 88 | 568,880 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | A | 8,334 | 27 | 228,852 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-07-01 | D | 10,176 | 87 | 889,789 | Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | D | 8,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sheldon Sloan | Chief Medical Officer | 2026-07-01 | D | 1,834 | 88 | 162,016 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-07-01 | D | 5,775 | 88 | 505,601 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-07-01 | D | 590 | 89 | 52,457 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 16 | 97 | 1,559 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 800 | 94 | 75,176 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 100 | 97 | 9,710 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 2,300 | 96 | 221,490 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | D | 5,100 | 95 | 485,571 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-08-03 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 5,635 | 96 | 540,566 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 7,157 | 95 | 680,631 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-08-03 | D | 1,392 | 97 | 134,773 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 5,000 | 104 | 522,350 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | A | 5,000 | 10 | 51,950 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 8,000 | 104 | 835,040 | Common | Form 4 ↗ |
| Jeffrey Albers | Director | 2026-08-07 | D | 10,000 | 105 | 1,046,800 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 400 | 89 | 35,628 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 8,400 | 87 | 732,060 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 2,500 | 86 | 215,900 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 200 | 89 | 17,808 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 27,999 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 400 | 89 | 35,752 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 6,206 | 88 | 547,183 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 16,548 | 87 | 1,442,986 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | A | 27,999 | 15 | 405,986 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-01 | D | 4,845 | 86 | 418,608 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 2,016 | 88 | 177,468 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 4,384 | 87 | 381,890 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-01 | D | 900 | 86 | 77,625 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-09-01 | D | 3,700 | 88 | 325,822 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-02 | D | 18,232 | 89 | 1,629,029 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-02 | D | 400 | 90 | 36,000 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-02 | A | 400 | 15 | 5,800 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-09-02 | D | 400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-30 | D | 17,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-30 | D | 17,500 | 90 | 1,573,075 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-09-30 | A | 17,500 | 15 | 253,750 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 2,600 | 93 | 242,996 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 2,100 | 93 | 194,670 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 7,228 | 91 | 660,278 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 16,605 | 90 | 1,500,262 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 400 | 89 | 35,696 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | A | 28,933 | 15 | 419,529 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 229 | 94 | 21,428 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 3,071 | 93 | 285,449 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 2,100 | 92 | 193,032 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 600 | 89 | 53,442 | Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | A | 7,500 | 15 | 108,750 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 100 | 94 | 9,391 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 4,990 | 93 | 465,916 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 3,989 | 92 | 368,225 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 2,638 | 91 | 241,351 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 2,683 | 90 | 241,738 | Common | Form 4 ↗ |
| Cameron Turtle | Director | 2026-10-01 | D | 600 | 89 | 53,484 | Common | Form 4 ↗ |
| Heidy King-Jones | See Remarks | 2026-10-01 | D | 28,933 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Burrows | Chief Financial Officer | 2026-10-01 | D | 1,500 | 90 | 135,405 | Common | Form 4 ↗ |
Sources (173 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Cameron Turtle. DEF 14A, filed 2026-04-10. Section “Executive Compensation”. As printed: 6,707,361. View filing ↗
- Section 01, Sheldon Sloan. DEF 14A, filed 2026-04-10. Section “Executive Compensation”. As printed: 2,211,805. View filing ↗
- Section 01, Heidy King-Jones. DEF 14A, filed 2026-04-10. Section “Executive Compensation”. As printed: 2,192,045. View filing ↗
- Section 01, Scott Burrows. DEF 14A, filed 2026-04-10. Section “Executive Compensation”. As printed: 2,192,045. View filing ↗
- Section 03, Cameron Turtle OPTION. DEF 14A, filed 2026-04-10. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Heidy King-Jones OPTION. DEF 14A, filed 2026-04-10. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Burrows OPTION. DEF 14A, filed 2026-04-10. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Sheldon Sloan OPTION. DEF 14A, filed 2026-04-10. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-10. Section “CEO Pay Ratio”. As printed: 15 : 1. View filing ↗
- Section 08, Jeffrey Albers. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 348,675. View filing ↗
- Section 08, Laurie Stelzer. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 313,675. View filing ↗
- Section 08, Sandra Milligan. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 306,175. View filing ↗
- Section 08, Michael Henderson. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 298,675. View filing ↗
- Section 08, Tomas Kiselak. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 296,175. View filing ↗
- Section 08, Peter Harwin. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 293,675. View filing ↗
- Section 08, Mark McKenna. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 288,675. View filing ↗
- Section 08, Cameron Turtle. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Cameron Turtle 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Henderson 2026-05-08. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Henderson 2026-05-08. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Henderson 2026-05-08. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Henderson 2026-05-08. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Milligan 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurie Stelzer 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Henderson 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fairmount Funds Management LLC 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark McKenna 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Albers 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Henderson 2026-06-22. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fairmount Funds Management LLC 2026-06-23. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fairmount Funds Management LLC 2026-06-23. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fairmount Funds Management LLC 2026-06-23. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheldon Sloan 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Albers 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Albers 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Albers 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Albers 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Albers 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cameron Turtle 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidy King-Jones 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Burrows 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 405,000 + equity 0 + all other 0 = 405,000, summed across the director compensation table rows.
- Stoke Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. View filing ↗
- Arcellx, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx, Inc.'s own proxy. As printed: 21,402,668. View filing ↗
- Janux Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Janux Therapeutics, Inc.'s own proxy. As printed: 13,506,231. View filing ↗
- Disc Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Disc Medicine, Inc.'s own proxy. As printed: 9,986,626. View filing ↗
- Kymera Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. View filing ↗
- Structure Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Structure Therapeutics Inc.'s own proxy. As printed: 8,429,887. View filing ↗
- Vera Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera Therapeutics, Inc.'s own proxy. As printed: 6,986,410. View filing ↗
- Spyre Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Spyre Therapeutics, Inc.'s own proxy. As printed: 6,707,361. View filing ↗
- Astria Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics, Inc.'s own proxy. As printed: 6,604,416. View filing ↗
- Nurix Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Nurix Therapeutics, Inc.'s own proxy. As printed: 6,374,138. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- Xencor Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor Inc.'s own proxy. As printed: 5,521,205. View filing ↗
- Pliant Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. View filing ↗
- Celldex Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. View filing ↗
- Contineum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Contineum Therapeutics, Inc.'s own proxy. As printed: 3,409,448. View filing ↗
- IGM Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. View filing ↗
- Keros Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics, Inc.'s own proxy. As printed: 2,540,204. View filing ↗
- Dyne Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. View filing ↗
- Apogee Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Apogee Therapeutics, Inc.'s own proxy. As printed: 1,291,500. View filing ↗
- Section 10a, Apogee Therapeutics, Inc. reciprocity. DEF 14A. Apogee Therapeutics, Inc. names Spyre Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Vera Therapeutics, Inc. reciprocity. DEF 14A. Vera Therapeutics, Inc. names Spyre Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Pliant Therapeutics, Inc. reciprocity. DEF 14A. Pliant Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Arcellx, Inc. reciprocity. DEF 14A. Arcellx, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Astria Therapeutics, Inc. reciprocity. DEF 14A. Astria Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, IGM Biosciences, Inc. reciprocity. DEF 14A. IGM Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Stoke Therapeutics, Inc. reciprocity. DEF 14A. Stoke Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, AnaptysBio, Inc. reciprocity. DEF 14A. AnaptysBio, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Celldex Therapeutics, Inc. reciprocity. DEF 14A. Celldex Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Keros Therapeutics, Inc. reciprocity. DEF 14A. Keros Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Xencor Inc. reciprocity. DEF 14A. Xencor Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Janux Therapeutics, Inc. reciprocity. DEF 14A. Janux Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Nurix Therapeutics, Inc. reciprocity. DEF 14A. Nurix Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Contineum Therapeutics, Inc. reciprocity. DEF 14A. Contineum Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Disc Medicine, Inc. reciprocity. DEF 14A. Disc Medicine, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Kymera Therapeutics, Inc. reciprocity. DEF 14A. Kymera Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Dyne Therapeutics, Inc. reciprocity. DEF 14A. Dyne Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗
- Section 10a, Structure Therapeutics Inc. reciprocity. DEF 14A. Structure Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Spyre Therapeutics, Inc.. View filing ↗